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Most complex trait-associated variants are located in non-coding regulatory regions of the
genome, where they have been shown to disrupt transcription factor (TF)-DNA binding motifs. Var-
iable TF-DNA interactions are therefore increasingly considered as key drivers of phenotypic vari-
ation. However, recent genome-wide studies revealed that the majority of variable TF-DNA binding
events are not driven by sequence alterations in themotif of the studied TF. This observation implies
that the molecular mechanisms underlying TF-DNA binding variation and, by extrapolation, inter-
individual phenotypic variation are more complex than originally anticipated. Here, we summarize
the findings that led to this important paradigm shift and review proposed mechanisms for local,
proximal, or distal genetic variation-driven variable TF-DNA binding. In addition, we discuss the
biomedical implications of these findings for our ability to dissect the molecular role(s) of non-
coding genetic variants in complex traits, including disease susceptibility.Introduction
Analysis of genomic variation in humans (Auton et al., 2015) as
well as in model species such as the mouse (Keane et al.,
2011; Yalcin et al., 2011) and fruit fly (Huang et al., 2014;Massou-
ras et al., 2012) is providing unprecedented opportunities to
understand the genetic basis of complex traits, including disease
susceptibility. An important insight that emerged from genome-
wide association studies (GWAS) is that the vast majority of
significantly associated genetic variants is located in non-coding
regions and may thus impact gene regulation. For example, of
465 unique trait/disease-associated single nucleotide polymor-
phisms (SNPs) derived from 151 GWAS studies, only 12% are
located in protein-coding regions, while 40% fall within introns
and another 40% in intergenic regions (Hindorff et al., 2009). In
addition, genome-wide profiling of accessible chromatin regions
using DNase I hypersensitivity (DHS) mapping revealed that
almost 60% of non-coding GWAS SNPs and other variants are
located within DHS sites, with another 20% being in complete
linkage disequilibrium (LD) with variants that lie in a proximate
DHS site (Maurano et al., 2012). Since DHS sites reflect the oc-
cupancy of DNA binding proteins such as transcription factors
(TFs), these data indicate that GWAS loci may alter the binding
of TFs and, as such, induce variation in gene expression and
ultimately in complex organismal phenotypes. In this Review,
we summarize the findings that led to this increasingly accepted
notion of the importance of variation in TF-DNA binding in medi-
ating phenotypic diversity. In addition, we strive to clarify why, for
the majority of studied traits or diseases, establishing a mecha-
nistic link between regulatory and phenotypic variation is still
very challenging.
For this purpose, we explore themolecular mechanismsmedi-
ating TF-DNA binding variation and address a major question in538 Cell 166, July 28, 2016 ª 2016 Elsevier Inc.the field—namely, why the majority of variable TF-DNA binding
events appear to be driven bymechanisms other than nucleotide
variation in the cognatemotifs.We thereby focus on human inter-
individual, molecular variation and restrict this Review to discus-
sing mechanisms underlying variable TF-DNA binding. Conse-
quently, we will only briefly cover the functional consequences
of this variation or other modes of regulatory variation, which
have been extensively detailed elsewhere both for humans and
model organisms (Albert and Kruglyak, 2015; Lehner, 2013;
Lowe and Reddy, 2015; Mackay et al., 2009; Pai et al., 2015).
A Brief Historical Perspective on Variable TF-DNA
Interactions as Key Drivers of Inter-individual,
Phenotypic Diversity
The discovery of regulatory sequences (or ‘‘operators’’) in bacte-
ria by Jacob andMonod initiated the debate of whether variation
in ‘‘regulator-operator’’ interactions could drive phenotypic di-
versity (Jacob and Monod, 1961). It was proposed that this vari-
ation could arise either throughmutations in the regulator itself or
through mutations in the operator that would ‘‘alter or abolish its
specific affinity for the repressor (i.e., regulator)’’ (Jacob and
Monod, 1961). This fundamental prediction proved to be accu-
rate across species, and multiple examples have since been
revealed that support both scenarios (Barrera et al., 2016; Hoek-
stra and Coyne, 2007; Lynch and Wagner, 2008; Wray, 2007).
The first concrete evidence supporting the importance of such
non-coding or regulatory variation for human traits or diseases
started to emerge in the early 1980s, when the molecular mech-
anisms underlying thalassemias were investigated. These herita-
ble blood disorders, characterized by an abnormal form of
hemoglobin, made it intuitive to explore the globin gene locus
for disease-causing genetic variants. Numerous variants were
detected, including several polymorphisms in the b globin gene
(HBB) promoter that correlated with reduced HBB expression
(Orkin et al., 1982; Poncz et al., 1982). For example, a single
nucleotide substitution (C to G) at position 87 of HBB’s tran-
scription start site (Orkin et al., 1982) was hypothesized to affect
the recruitment of a transcriptional activator. However, it was
only 11 years later, when the erythroid Kru¨ppel-like factor
(KLF1) was cloned, that the affected site (CA(C/G)CC) was
matched with a TF (Miller and Bieker, 1993) (Table 1). This
groundbreaking example (as well as several others listed in
Table 1) support the idea of TF-DNA interactions being key
drivers of phenotypic variation. However, the fact that the under-
lying molecular mechanisms were uncovered for these diseases
is still more the exception than the rule.
Assessing the Impact of Genetic Variation on TF-DNA
Binding: A Complex Affair
The ability to elucidate the molecular mechanisms underlying
thalassemia, haemophila B, or malaria resistance was made
possible because several critical pieces of information were
available that are often missing in other genotype-phenotype
relationship studies: (1) knowledge of the affected gene, which
facilitated the identification of the causal mutation(s); (2) avail-
ability of DNA binding specificity data for the implicated TF;
and (3) relatively straightforward imputation of the effect of the
causal mutation(s) on TF-DNA binding. Below, we will discuss
each of these three items in more detail and explain why they
collectively complicate studies that investigate the impact of ge-
netic variation on molecular or organismal variation.
Identification of Causal Mutation(s) and Affected
Gene(s)
In contrast to cases like the thalassemia mutations discussed
above, GWAS studies identify genetic variants linked to partic-
ular traits, but not necessarily those actually causing the disease
(Manolio, 2013). In addition, such studies do generally have little
prior knowledge regarding which genes will be uncovered.
Therefore, by simply matching a GWAS SNP with a TF binding
site, one risks wrongly inferring that a TF must affect the expres-
sion of the gene that is most proximal to a particular binding site.
However, the actual culprit could be another genetically linked
but unprobed variant such as an indel or a rare SNP that impacts
a different binding site and thus a distinct TF and/or target gene.
This potential misidentification is why significant efforts are
currently undertaken to fine-map complex traits using statistical
arguments (Figure 1; see also the ‘‘Imputing DNA binding varia-
tion’’ section) and/or integrative genomic approaches to identify
causal variants and their target genes at nucleotide-level resolu-
tion. A striking recent example involves variants that have been
consistently associated with an elevated body mass index in
both children and adults (Dina et al., 2007; Frayling et al.,
2007). These variants are located in the first and second introns
of a large (>250 kb) gene named fatso, or FTO, because its dele-
tion causes a fused toes phenotype in mouse (Peters et al.,
1999). Given its association with obesity, it was subsequently re-
phrased as fat mass and obesity-associated gene and was
widely mechanistically studied for its role in energy homeostasis
(Fischer et al., 2009). However, recent studies revealed that the
focal variants are, in fact, located in a regulatory element thatcontrols the expression of the TF-coding genes IRX3 and IRX5
more than 1 Mbp away (Claussnitzer et al., 2015; Smemo
et al., 2014). Thus, these variants appear to have little impact
on the FTO gene, even though they are positioned within its in-
trons. Rather, one variant disrupts the binding site of ARID5B
(AA(T/C)ATT), resulting in elevated IRX3 and IRX5 expression.
This, in turn, increases the formation of white fat cells, possibly
leading to excessive fat accumulation (Claussnitzer et al.,
2015). Significant efforts involving a battery of advanced compu-
tational (Claussnitzer et al., 2014) and experimental approaches
were required to study the molecular function of the ‘‘FTO
variants’’ and their relationship with body mass index. This
complexity illustrates why the number of mechanistically well-
studied relationships between regulatory and phenotypic varia-
tion is still relatively low. It also explains why the majority of
such studies focused on gene proximal variants (Table 1), espe-
cially prior to 2005, when the importance of chromosome confor-
mation in gene regulation was still less established.
Incomplete TF Motif Catalog
In the early 1990s, DNA binding variation of the TFs CEBPa and
HNF4A, as well as GATA1, was linked to, respectively, haemo-
philia B and malaria resistance (Table 1). The identification of
these TFs is intuitive since they were among the relatively few
TFs whose DNA binding properties had been described at the
time when these genetic studies were carried out (Faisst and
Meyer, 1992). Several other studies have since established reg-
ulatory variant-phenotype relationships on the basis of GATA1
(Table 1), illustrating how such studies tend to be restricted to
investigating phenotypes that involve well-characterized TFs.
While the development of several large-scale in vitro DNA
binding characterization technologies, such as protein-binding
microarrays (PBM) (Berger et al., 2006), bacterial one-hybrid
(B1H) screening (Meng et al., 2005), and high-throughput (HT)-
SELEX (Jolma et al., 2010), has enabled a significant expansion
of the TF motif catalog, it is worth noting that at least one-third of
human TFs remains uncharacterized (Box 1). In other words,
several hundred TFs are still devoid of DNA binding specificity
models such as the most routinely used position weight matrix
(PWM) (Stormo and Zhao, 2010) (Figure 1). This lack of informa-
tion severely limits the ability to analyze the effects of genetic
variation on TF-DNA binding, as a large fraction of human TFs
can simply not be taken into account in such studies.
This problem becomes even larger when considering that
many TFs do not bind DNA as single entities but, rather, in the
form of obligate heterodimers such as TFs containing bZIP,
bHLH, MADS box, or Rel DNA binding domains. Since the focus
of DNA binding specificity determination studies has largely
been on single protein-DNA interactions, DNA binding motifs
for such heterodimers are underrepresented in current regula-
tory lexicons. Moreover, many TFs also participate in facultative
heterodimers since they can bind to DNA both in monomeric or
dimeric context. It is difficult to know how many of such hetero-
dimers routinely form in cells, but predictions range from 3,000
(Ravasi et al., 2010) to >25,000 (Jolma et al., 2015). Interestingly,
these cooperative TF pairs often show distinct binding site
preferences compared to the respective, individual TFs, as the
heterodimer core motif typically consists of closely packed indi-
vidualmotifs that overlap at their flanks. Consequently, individualCell 166, July 28, 2016 539
Table 1. Examples Linking Variable TF-DNA Binding to Phenotypic Variation Arranged by Date of Characterization
Phenotype Affected Gene
Causal Variant Position
Relative to TSS
Affected Binding
Site
TFBS
Outcome Reference(s)
Hereditary persistance of fetal
haemoglobin
HBG 175 bp GATA1; TAL1 Gain (Martin et al., 1989;
Wienert et al., 2015)
Haemophilia B Leyden F9 20 bp; 10 bp; 6 bp HNF4a; C/EBPa;
OC1/OC2
Loss (Reijnen et al., 1992;
Crossley and Brownlee,
1990; Funnell et al., 2013)
Haemophilia B Brandenburg F9 26 bp AR Loss (Crossley et al., 1992)
Delta-thalassemia HBD 77 bp GATA1 Loss (Matsuda et al., 1992)
Duffy blood antigen/chemokine
receptor expression
DARC 46 bp GATA1 Loss (Tournamille et al., 1995)
Familial combined hyperlipidemia LPL 39 bp OCT1 Loss (Yang et al., 1995)
Bernard-Soulier syndrome GP1BB 133 bp GATA1 Loss (Ludlow et al., 1996)
Osteoporosis COLlAl +2 kb Sp1 Gain (Grant et al., 1996)
Maturity-onset diabetes of the
young
HNF1A 58 bp HNF4A Loss (Gragnoli et al., 1997)
Asthma IL10 509 bp YY1 Gain (Hobbs et al., 1998)
Pyruvate kinase deficiency PKLR 72 bp GATA1 Loss (Manco et al., 2000)
Congenital erythropoietic porphyria UROS 70 bp; 90 bp GATA1; CP2 Loss (Solis et al., 2001)
Psoriasis SLC9A3R1 237 bp RUNX1 Loss (Helms et al., 2003)
Systemic lupus erythematosus FASLG 844 bp CEBPB Loss (Wu et al., 2003)
Esophageal cancer COX-2 1195 bp c-MYB Gain (Zhang et al., 2005)
Treacher Collins syndrome TCOF1 346 bp YY1 Loss (Masotti et al., 2005)
Alpha-thalassemia HBA 13 bp GATA1 Gain (De Gobbi et al., 2006)
Holoprosencephaly SHH 460 kb SIX3 Loss (Jeong et al., 2008)
Various cancers TERT 187 bp ETS2 Loss (Xu et al., 2008)
Nonsyndromic cleft lip IRF6 14 kb AP2 Loss (Rahimov et al., 2008)
Pierre Robin syndrome SOX9 1.44 Mb MSX1 Loss (Benko et al., 2009)
Prostate cancer MYC 200 kb FOXA1 Gain (Jia et al., 2009)
Colorectal cancer MYC 300 kb TCF7L2 Gain (Tuupanen et al., 2009)
Asthma and autoimmune diseases ZPBP2;
GSDMB;
ORMDL3
5 kb; +44 kb; +54 kb CTCF Loss (Verlaan et al., 2009)
Myocardial infarction SORT1 44 kb CEBPA Loss (Musunuru et al., 2010)
Beta-thalassemia HBB 71 bp GATA1 Loss (Al Zadjali et al., 2011)
Coagulant factor VII deficiency F7 60 bp HNF4A Loss (Zheng et al., 2011)
Osteoarthritis GDF5 41 bp YY1 Loss (Dodd et al., 2013)
Breast cancer CCND1 127 kb; 76 kb ELK4; GATA3 Loss; Gain (French et al., 2013)
Melanoma, various cancers TERT +2bp; 66 bp; 88 bp ETS2 Gain (Horn et al., 2013)
(Huang et al., 2013)
Increased cancer susceptibility KITLG +20 kb P53 Loss (Zeron-Medina et al., 2013)
Hirschsprung disease SOX10 30 kb AP2; SOX10 Loss (Lecerf et al., 2014)
Insulin resistance PPARG2 6 kb PRRX1 Loss (Claussnitzer et al., 2014)
Type 2 diabetes and proinsulin-
decrease
ARAP1 +418 bp PAX6/PAX4 Loss (Kulzer et al., 2014)
Melanoma SDHD 25 bp; 7 bp; 4 bp EHF, ELF1 & ETS1 Loss (Weinhold et al., 2014)
Pancreatic agenesis PTF1A 25 kb FOXA2, PDX1 Loss (Weedon et al., 2014)
Acute lymphoblastic leukemia TAL1 7.5 kb MYB Gain (Mansour et al., 2014)
Obesity and Type 2 diabetes IRX3; IRX5 0.5 Mb; 1.2 Mb ARID5B Loss (Claussnitzer et al., 2015)
Colorectal cancer FASLG 1377 bp; 670 bp SP1; STAT1 Loss (Wang et al., 2016)
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Figure 1. A Methodological Workflow for Identifying Regulatory Variants
Sequence-based, computational methodologies that evaluate the impact of potential regulatory variants on TF-DNA binding and downstream regulatory pro-
cesses are schematically presented. For every putative variant (SNV, as in this example, or indel), a reference and alternate (containing the variant) sequence of
pre-defined length (illustrated by the distinct shades of gray) is extracted. The chosen length defines the ‘‘sequence environment’’ and varies according to the
type ofmodel that is used. Themiddle yellow panel shows the commonworkflow, where both sequences are scored (SALT and SREF) according to a specificmodel
representation to obtain a differential score (DS) that may indicate a change in DNA binding or more generally in chromatin state. As shown, DS supports a model
in which the variant impacts a gene regulatory process. The bottom part of the figure illustrates the two main strategies that are employed for modeling the
regulatory effect of a variant. The choice of the strategy depends on the posed question: does the variant impact (1) the binding of a TF (left) or (2) the local
chromatin landscape (right)? In the first scenario, computational methods are used that depend on the availability of a comprehensive catalog of TF binding
sequences or motifs (Box 1). The ‘‘de novo motif discovery’’ part schematizes the procedure that is required to obtain such a catalog, illustrating the use of
sequence over-representation strategies that are applied on both in vivo (ChIP-seq, DHS-seq, etc.) and in vitro (e.g., PBM, HT-SELEX, or B1H) derived datasets.
These strategies then produce TF motifs that can be represented either in regular expression format or using PWM- or HMM-based models. In this example, the
linear HMMmodel is a generic representation of the PWMmotif, with each node (state) of the HMM representing the position of a base in the motif. Additionally, a
second HMM model is depicted, which inherently takes a variable space within the motif into account, for accurate representation of more complex binding
scenarios (e.g., TF dimers). To answer the second question (lower-right), computational methods mainly rely on machine learning models that are trained on a
wide variety of features such as a k-mer vocabulary built on regulatory versus background sequences or additional (epi)genomic datasets. These more elaborate
models can also be used to score the two input sequences. The pipeline then evaluates the regulatory nature of the variant by directly assessing the differential
score DS or by calculating a p value based on the distribution of the scores. Of note, this pipeline can be applied multiple times on different variants, after which
the results can be aggregated and compared to prioritize variants.
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Box 1. How Many Human TFs Have Assigned Motifs?
While seemingly straightforward, it turns out to be difficult to precisely enumerate the number of TFs with defined motifs. There is no consensus on
the number of TF-coding genes in the human genome. A comprehensive, manual curation primarily based on the presence of sequence-specific
DNA binding domains revealed 1,391 high-confidence genes, with another 216 listed as plausible (Vaquerizas et al., 2009). However, this list
may not be exhaustive as a protein microarray-based survey of DNA binding capacity revealed that hundreds of proteins among 3,000 that
were not annotated as TFs were able to bind to DNA in a site-specific manner (Hu et al., 2009). Thus, additional experimental efforts will be required
to derive amore precise estimate of the number of TFs that the human genome encodes. Therefore, we need to simplify the question to howmany of
the1,400 high-confidence TFs have annotatedmotifs. A very recent, expansive analysis involving almost 1,000 high-quality ChIP-seq and 542 HT-
SELEX datasets produced binding site models for 601 human TFs that are retrievable from the HOCOMOCO database (Kulakovskiy et al., 2016).
Why only 40% of human TFs feature experimentally derived motifs despite the development of powerful DNA binding characterization technol-
ogies such as PBM (Berger et al., 2006), bacterial one-hybrid (B1H) (Meng et al., 2005), or HT-SELEX (Jolma et al., 2010) is unclear but may largely
be due to technical limitations, including loss of DNA binding properties or weak in vitro expression of full-length proteins. This is why most in vitro
DNA binding assays rely on analysis of the DNA binding domains (DBDs) of TFs, as these are easier to work with in terms of cloning and expression
while exhibiting DNA binding properties that appear largely comparable to the respective full-length protein versions (Jolma et al., 2013).
The largest TF families that still resist a comprehensive characterization are the high-mobility group (HMG) TFs and C2H2 zinc finger proteins (Jolma
et al., 2013), of which the human genome encodes more than 700 (Weirauch and Hughes, 2011). Progress is being made though, as illustrated by a
recent study that combined PBMs and B1H assays to probe thousands of individual C2H2 zinc finger domains with the aim of inferring a specific
DNA recognition code (Najafabadi et al., 2015). The resulting motifs proved to be highly diverse in terms of nucleotide composition and exhibited
extensive degeneracy, whichmeans that thesemotifs can be represented bymany different sequences and that small internal perturbations in these
motifs tend to have little impact on DNA binding. Consequently, there is still ample room for alternative approaches or technologies that will enable
the further expansion or fine-tuning of the current catalog of human TF PWMs, also named the ‘‘human regulatory lexicon.’’
Nevertheless, it may not be necessary to gather experimental data for all TFs, given that many have nearly identical DNA binding properties because
their DBDs are highly similar. Indeed, TFs (independent of organism) whose DBDs share >87.5% of their amino acids were found to bind to motifs
that were almost indistinguishable from one another (Weirauch et al., 2014). Applying this principle to human TFs adds another 200 inferred motifs to
the current catalog, which can be found in the Cis-BP database (Weirauch et al., 2014). In sum, the DNA binding properties of a significant fraction of
human TFs remain uncharacterized without even taking into account heterodimer or higher-order complex formation (see main text).TFs may still be able to bind to this core motif, albeit with much
lower affinity. This may, in part, explain the observed discrep-
ancy between in vivo DNA occupancy levels and in-vitro-derived
DNA binding affinities (Biggin, 2011), since these in vivo binding
events may reflect binding by interacting TF pairs and not indi-
vidual TFs. It is therefore clear that a large portion of motifs
remain to be characterized, emphasizing the need for new tech-
nologies or efforts to close this gap.
Imputing DNA Binding Variation
It has often proven difficult to infer whether a specific polymor-
phism will significantly change TF-DNA binding and act as a
regulatory variant, even if the PWM model of the TF is available.
This complication stems from difficulties in capturing the
DNA binding complexity of a TF in a robust binding model either
to confidently detect a genuine binding site within a given
sequence or to accurately infer the impact of a variant on de-
tected motifs.
The Accuracy of Binding Models and Robustness of Motif
Detection. The majority of motif detection methodologies rely
on PWM representation since PWMs perform relatively well
with respect to capturing the overall binding affinity. This is
because PWMs can be modeled as a numerical matrix, which
enables the scoring of a given sequence according to its similar-
ity to a motif (Figure 1). Nevertheless, it is important to acknowl-
edge that this model also has several limitations, which may
impede the discovery of the correct binding patterns. For
example, PWM models assume that the nucleotide binding en-
ergies are independent (Stormo and Zhao, 2010), which proved
not to be generally valid (Bulyk et al., 2002; Jolma et al., 2013;
Maerkl and Quake, 2009; Nutiu et al., 2011), and are also subop-
timal to represent the binding of TF dimers, since many of these542 Cell 166, July 28, 2016bind to two sequences that are separated by a spacer with var-
iable length. These caveats have spurred the development of
different models for representing TF motifs, such as hidden Mar-
kov models (HMMs) (Gelfond et al., 2009; Zhao et al., 2005) and
more advanced machine learning models, stimulated by the
increasing availability of multiple layers of genomic, transcrip-
tomic, and epigenomic information. Among these are support
vector machine (SVM) or neural network (NN) approaches that
are trained on datasets containing both known regulatory and
random sequences, with the goal of recognizing and scoring
new putative regulatory sequences (Gao and Ruan, 2015)
(Figure 1 and Table S1). Such representations havemany advan-
tages over conventional models because they are highly flexible.
In addition, they are not limited to the DNA sequence recognized
by the TF and can incorporate additional features that are also
important to model TF-DNA binding. These features include
the 3D structural conformation of DNA and its steric characteris-
tics (Levo and Segal, 2014; Rohs et al., 2009; Zhou et al., 2015),
the chemical properties used to model TF amino acid-nucleotide
contacts at the atomic level (Bauer et al., 2010; Maienschein-
Cline et al., 2012), protein concentration (Djordjevic et al.,
2003; Wang and Batmanov, 2015) that allows for a more accu-
rate estimation of DNA occupancy and thus intrinsic DNA bind-
ing affinity (Biggin, 2011; Simicevic et al., 2013), and, finally,
the nucleotide composition of motif-neighboring sequences.
Indeed, recent work revealed that the sequence environment
of a genuine binding site tends to be distinct from that of un-
bound sequences. In particular, it was shown to exhibit specific
sequence features such as high GC content (White et al., 2013)
or a higher similarity to the core motif (Dror et al., 2015) that
may guide TFs to their cognate binding sites. These findings
have important consequences in terms of predicting DNA
binding events, since motif-scanning tools typically penalize for
local nucleotide composition biases. Instead, a better practice
may now involve rewarding motifs that are surrounded by estab-
lished DNA binding-promoting features, such as a high GC frac-
tion or lower-scoring and thus weaker homotypic (i.e., similar)
motifs. Together, these studies illustrate that the formulation of
DNA binding models and computational detection of genuine
binding sites is far from trivial and that further efforts aimed at
integrating a wide range of genomic datasets will be required
to increase the robustness of motif definition and mapping
approaches.
The Complexity of Correctly Inferring the Effect of Motif Varia-
tion on TF-DNA Binding. Genetic variants that change a TF motif
often affect the binding ability of a TF to that site because of an
altered DNA binding affinity (Table 1 and Figure 1). Initial efforts
to computationally predict relevant regulatory variants simply
revolved around the consideration of all SNPs that overlap with
TF binding sites (Ameur et al., 2009; Chorley et al., 2008; Pono-
marenko et al., 2001). However, given the degenerate nature of
binding motifs (i.e., binding is not binary but is variable depend-
ing on different sequences), these kinds of analyses tend not to
provide good sensitivity. A more refined approach in this regard
is to analyze the difference in DNA binding affinity (for example,
scored using a PWM) between two alleles, i.e., the reference and
the alternate impacted by the variant (Figure 1 and Table S1). The
greater this difference, the greater the predicted impact of the
variant on binding of the respective TF and thus also the greater
the likelihood of it being causal.
More recent machine learning methods no longer depend on
the use of a strict motif database and directly infer regulatory
effects from k-mer vocabularies trained on ChIP-seq or other
experimental data. These vocabularies consist of all possible
DNA sequences of length k that collectively capture specific
sequence properties of certain regulatory elements such as
cell-type-specific enhancers. This methodological development
stems from the general appreciation in the field that the motif
alone cannot accurately predict differential DNA binding and
thus should be complemented (or even replaced) with informa-
tion on the sequence environment around the focal variant, as
well as on other DNA or chromatin features that enhance the
model’s overall predictive power (as already covered in the pre-
vious section). Indeed, it is nowwell accepted that only aminority
of motif-disrupting variants effectively result in altered DNA bind-
ing of the respective TF (Heinz et al., 2013; Kilpinen et al., 2013;
Maurano et al., 2015; Spivakov et al., 2012). One possible expla-
nation is based on the finding that, across the genome, TFmotifs
appear to occur in clusters with some built-in redundancy (Gotea
et al., 2010), in line with the observation that the sequence
environment of relevant TF binding sites tends to have a certain
similarity to the core motif (Dror et al., 2015). These clustered
sites may buffer genetic perturbations that affect one of the
motifs. Indeed, the greater the number of such homotypicmotifs,
the greater the buffering effect (Kilpinen et al., 2013). Given
the pervasive nature of this buffering phenomenon (Maurano
et al., 2015), the failure to take such neighboring homotypic
motifs into account may result in false TF-DNA binding event
predictions.More generally, epigenomic properties such as nucleosome
location (Soufi et al., 2015) or density (Barozzi et al., 2014) or
DNA methylation (Domcke et al., 2015) may impact the ability
of a TF to bind to a certain DNA sequence. Upon screening
1,300 human TFs for their ability to bind to one of 150 distinct
CpG-containing motifs, 47 were found to bind to DNA with
several exhibiting methylation-specific DNA specificities (Hu
et al., 2013). This is consistent with an earlier study demon-
strating that the TF Kaiso is capable of binding not only to an
unmethylated motif, TCCTGCNA, but also to a methylated,
clearly distinct palindromic motif, TCTmCGmCGAGA, with
even greater affinity (Raghav et al., 2012). How frequently such
methylation-dependent changes in DNA binding occur and the
extent to which other DNA modifications affect DNA binding
specificities is still a matter of debate. Nevertheless, it is clear
that it adds another complexity in linking DNA variation to vari-
able TF binding.
Ongoing computational studies are attempting to take these
complexities into account by implementing ‘‘big data’’ analyses
that are creating extended machine learning models that rely on
multilayered information of different types of genomic data,
including TF motifs, DNase hypersensitivity sites (DHS), chro-
matin marks, etc. (see, for example, Table S1). As such, they
can recognize regulatory regions based not only on pure
sequence information, but also on the chromatin state of the
DNA both at the variant locus as well as at neighboring regions.
Once correctly trained, these approaches can be very precise
and predict causal variants and their effects at distinct molecular
levels (Alipanahi et al., 2015; Zhou and Troyanskaya, 2015)
(Figure 1).
However, it is important to emphasize that their performance
depends not only on the diversity of input data, but also on the
correct selection of relevant features. For example, it has been
repeatedly shown that it is crucial to gather data that are specific
to the variant-linked trait or disease in terms of cell type, differen-
tiation stage, tissue, or species since regulatory activity is vari-
able and context dependent (Consortium, 2012; Maurano
et al., 2015). Another limitation of these extended representation
models that may dampen their widespread implementation is
their inherent ‘‘black box’’ nature. Indeed, most of the binding
patterns that were unveiled by these techniques are difficult to
interpret, especially when no visual representation is provided.
However, despite these caveats, advanced models have the
potential of uncovering completely novel and potentially unex-
pected cross-mechanisms that more standard methodologies
may fail to grasp.
TF-DNA Binding Is Itself a Complex, Molecular Trait
We are currently limited in our ability to predict TF binding as well
as in our understanding of how genetic variation impacts on this
process. Nevertheless, there is general consensus that differen-
tial, regulatory control by TFs is a major driver of phenotypic vari-
ation. A key aspect of this regulatory variation is variable TF-DNA
binding. It is in this regard intriguing that only a minority of vari-
able TF binding events are driven by nucleotide changes in the
motifs of the studied TFs. For example, upon assessing binding
variation of the TF NFKB in ten distinct human lymphoblastoid
cell lines (LCLs), only 79 out of >1,100 variable TF-DNA bindingCell 166, July 28, 2016 543
Figure 2. Distinct Modes of Genetic Variation-Mediated Changes in TF-DNA Binding
(A) Only a minority of variable TF-DNA binding events are caused by DNA variants disrupting the cognate TF recognition motif.
(B–D) Themajority of variably binding events aremotif variation independent, signifying that a variant located either proximally (<200 bp,BandC) or distally (D) to the
focal motif affects the binding of the respective TF. Proximal variants can affect local cooperative DNA binding (B), which involves physical protein-protein in-
teractions that require overlapping or very closely located (a few bp) motifs, or collaborative DNA binding (C), which reflects TF interdependencies needed, for
example, to compete with nucleosomes and thus to access DNA. In contrast, distal variants (D) may alter chromatin state or conformation (e.g., DNA loops), which
could affect the stability of interactions with DNA and between TFs.events had a SNP directly located in the NFKBmotif and induced
a binding difference that was consistent with its perceived
impact on motif quality (i.e., reduced binding was linked to a
SNP that lowered the PWM binding score and vice versa)
(Kasowski et al., 2010). One of the possible reasons that were
listed (next to LD or putative epigenomic variation) involved
trans-effects. However, ChIP-seq analyses of >20 TFs revealed
extensive, allele-specific DNA binding (in a constant trans
environment), effectively refuting this hypothesis (Reddy et al.,
2012). Subsequent studies in human LCLs and in cells or
tissues derived from distinct mouse strains observed a similar
pattern (Heinz et al., 2013; Kilpinen et al., 2013; Soccio et al.,
2015; Stefflova et al., 2013), collectively emphasizing the impor-
tance of cis-regulatory variation. Importantly, only a minority
of differential allelic occupancy events involved nucleotide
changes in the respective motifs (Reddy et al., 2012). However,
this does not mean that variation in the motifs of other TFs
should also be dispensed as a possible molecular mecha-
nism for these observations—quite the contrary, in fact, as we
will clarify in greater detail in the next paragraphs (see also
Figure 2).
If a particular genetic variant does not affect the motif of the
studied TF, what then causes the respective TF to exhibit differ-
ential DNA binding? It appears that an important fraction (at least
7.5% according to our own estimate [Kilpinen et al., 2013]) of
variable TF-DNA binding events can be explained by alterations
of proximal motifs (Reddy et al., 2012). Thus, at some genomic
sites, TFs appear to be dependent on the proximal presence of
other TFs to bind to DNA. Qualitative motif analysis combined
with prior knowledge about the biological process in which the
focal TF is operational lends credibility to this notion. For
example, in mouse white adipose tissue, PPARg binding sites
that vary between strains and do not harbor an altered PPARg
motif were analyzed for enriched, polymorphic motifs. The top-
scoring motifs corresponded to the TFs CEBPa and gluco-
corticoid receptor (Soccio et al., 2015) that exhibit extensive
co- localization with PPARg in mature white fat cells (Siersbæk
et al., 2014). Similarly, differential PU.1 binding correlated with544 Cell 166, July 28, 2016alterations in the motifs for the TFs CEBP and AP-1, which
modulate macrophage activity (Heinz et al., 2013). However,
this correlation appears to differ according to macrophage sub-
type. Indeed, a follow-up study in mouse microglia revealed that
other TF motifs correlate better with variable PU.1 DNA binding,
emphasizing the importance of cellular context in determining
this type of TF interactions (Gosselin et al., 2014). Together,
these studies strongly support the notion of pervasive DNA bind-
ing whose occurrence is dependent on the presence of other
TFs. Since it is well appreciated that regulatory regions tend to
harbor binding sites for multiple TFs, this notion may not be
entirely surprising. Nevertheless, it is worthwhile in the current
context of genetic variation to briefly revisit this mode of DNA
binding, which is interchangeably called cooperative or collabo-
rative DNA binding (Gosselin et al., 2014; Mirny, 2010; Slattery
et al., 2014; Waszak et al., 2015). We would thereby like to argue
that, for the sake of discussion and molecular understanding, it
might be valuable to differentiate between these two terms
(Figure 2).
Local, Cooperative TF-DNA Binding
In the context of protein-DNA interactions, cooperativity was
initially used in describing the assembly of E. coli lambda re-
pressors on DNA (Ptashne et al., 1980). Binding of a lambda
dimer on a first operator site facilitates binding of another
lambda dimer on the second operator site, given that physical
interactions between the first and second dimer increase the
affinity of the latter for DNA, which explains why ‘‘cooperative
DNA binding’’ is evoked to define this process. Consequently,
the term cooperativity may be especially suited for DNA binding
processes that involve TFs whose physical interactions at the
protein level may increase the affinity of the entire complex to
specific sites in the genome. For example, binding of the winged
HTH DNA binding domain-containing TF IRF4 is cooperatively
enhanced by the TF PU.1 (Escalante et al., 2002). This is
because binding of the two TFs contorts the DNA in a peculiar
S shape, placing the TFs in an optimal position for electrostatic
and hydrophobic interactions and thus stabilizing the entire
complex (Escalante et al., 2002). Consequently, individual
nucleotide alterations in one of the two binding sites may alter
the extent of cooperativity between two heterodimerizing TFs,
as has recently been quantified for the PPARg-RXRa hetero-
dimer (Isakova et al., 2016). This, in turn, illuminates why the
disruption of either of the two TF motifs tends to affect binding
of the respective heterodimer.
Proximal, Collaborative TF-DNA Binding
For TFs to physically interact on DNA and thus for cooperative
DNA binding to occur, one would intuitively expect that the
respective motifs would be located very close to one another
or would even overlap. However, DNA binding relationships exist
between TFs whose motifs are separated tens, hundreds, or
even thousands of base pairs from one another. For example,
upon examining which TFs (based on motif matches) associated
with NFKB binding enrichment (based on ChIP-seq data), EBF1
and STAT1 were among the most correlated TFs (Karczewski
et al., 2011). Interestingly, this covariation signal of EBF1 and
STAT1 motifs within variable binding regions of the TF NFKB re-
mained significant up to 500 bp from the NFKB binding peak cen-
ter, suggesting that DNA binding dependencies between these
TFs were maintained over a relatively long distance. It is now
increasingly appreciated that many such dependencies do not
require direct contacts but instead reflect a relatively well-under-
stood phenomenon termed collaborative DNA binding in which
two or more TFs compete with a nucleosome to access DNA
(Biggin, 2011; Mirny, 2010; Spitz and Furlong, 2012) (Figure 2).
Given that the intrinsic affinity of a nucleosome for DNA is
much greater than that of a TF alone (Polach and Widom,
1996), it may often require two or more collaborating TFs to
displace the nucleosome. In this scenario, TFswould bemutually
dependent, and this is indeed what is observed. For example,
HNF4A and CEBPa functioning in mouse liver exhibit a mutual
dependency, given that loss of HNF4A affected CEBPa DNA
binding and vice versa, whereas the absence of HNF4A did not
impact on the DNA binding dependency between CEBPa
and FOXA1 (Stefflova et al., 2013). A similar DNA binding interde-
pendency was found between PU.1 and CEBPa in primary
macrophages (Heinz et al., 2013). It is worth noting that such
nucleosome-mediated, collaborative DNA binding could still be
regarded as a form of indirect, cooperative DNA binding, as
modeling has revealed an analogy between this process and
the one involving cooperative binding of oxygen to hemoglobin
(Mirny, 2010). Nevertheless, to avoid confusion, it may be best
to continue to define this process as collaborative DNA binding.
Interestingly, several of these collaborating TFs have previ-
ously been defined as pioneer TFs that are uniquely able to ac-
cess and open silent or compacted chromatin (Iwafuchi-Doi
and Zaret, 2014). The fact that, at a wide range of loci, they are
nevertheless dependent on other TFs to access DNA constitutes
in this regard an intriguing paradox. For example, FOXA1 is
defined as an archetypical pioneer TF (Mancini and West,
2015), given its ability to open closed chromatin by binding to
DNA with its core DNA binding domain and to core histones
with a binding motif that is located in its C terminus (Cirillo
et al., 2002). However, its DNA binding interdependency with
CEBPa or potentially other TFs suggests that FOXA1’s ‘‘pioneer-
ing’’ ability may often not be sufficient to allow DNA binding,
implying that FOXA1 requires the cumulative contribution ofother TFs to displace nucleosomes and successfully unlock
chromatin. This model may be consistent with the dispensability
of FOXA1 and the related TF FOXA2 in maintaining the chromatin
state in liver cells (Li et al., 2012). Similarly, PU.1 is also recog-
nized as a pioneer factor for its ability to promote nucleosome
depletion (Barozzi et al., 2014; Heinz et al., 2010), yet it depends
on CEBP TFs to bind DNA at many genomic sites. What emerges
is that, at some loci, these TFs may act as true pioneer TFs,
whereas at others, they may require collaborations with other
TFs to open chromatin.
Consequently, it is of interest to better understand what distin-
guishes genomic sites with pioneer activity from collaborative
ones. An interesting observation in this regard is that regions
with high PU.1 occupancy in primary macrophages had, in gen-
eral, similar motif scores to those with lower PU.1 binding, but
the two types of regions differed in nucleosome organization
(Barozzi et al., 2014). Specifically, the latter regions were sur-
rounded by two nucleosomes (in contrast to sites with high
PU.1 binding) and showed enrichment for the NFKB motif, sug-
gesting that, at those regions, PU.1 and NFKB need to collabo-
rate to outcompete nucleosomes and thus to achieve high
DNA occupancy. As such, TFsmay have locus-dependent TF in-
terdependencies reflecting both nucleosome structure and the
presence of distinct TFmotif clusters, consistent with the depen-
dency of PU.1 on NFKB at some sites or either OCT2, BLIMP1,
or STAT2 at others in human LCLs (Kilpinen et al., 2013). This
view is also consistent with the flexible binding site grammar
that is typically observed in enhancers in that the position of in-
dividual TF motifs within enhancers tends to be of secondary
importance to their simple presence (Arnosti and Kulkarni,
2005). In other words, since collaborative DNA binding does
not require physical contacts, the spacing and orientation of mo-
tifs can be flexible with respect to preserving enhancer activity,
as long as the motifs are intact. This also implies that, at collab-
orative genomic sites, TFs should in principle bind to DNA in
seemingly joint fashion since loss of one TF-DNA interaction
(either in cis [e.g., because of a DNA mutation] or in trans
[because of TF dysfunction]) would reduce the binding capacity
of all other TFs at this locus. Such ‘‘collective’’ DNA binding
behavior has indeed been observed for TFs mediating heart
development in Drosophila melanogaster (Junion et al., 2012),
and evidence for simultaneous, collaborative TF-DNA binding
is also available for mammals (Adam et al., 2015; Siersbæk
et al., 2014; Tijssen et al., 2011). A final illustration of this impor-
tant notion is the dependency of the pioneer TF NRF1 (Sherwood
et al., 2014) on other TFs to keep a specific set of its target sites
from being methylated, which otherwise would block NRF1 DNA
binding to these sites (Domcke et al., 2015). This example again
illuminates how sequence context may affect the ability of a TF to
bind independently to DNA, even if this TF may normally act as a
pioneer factor. In sum, based on the currently available data,
care needs to be taken when classifying TFs into specific cate-
gories without considering sequence and chromatin context.
Variable Chromatin Modules Mediate Long-Range
TF-DNA Binding Interdependence
The previous sections highlighted that proximal variants can
affect DNA binding through cooperative or collaborative mecha-
nisms. However, many of the variants that drive TF-DNA bindingCell 166, July 28, 2016 545
variation are located beyond the sequence span that is required
for the formation of local TF-TF interactions or for competition
with local nucleosomes, respectively. One possibility is that pro-
teins overcome this distance restraint by inducing DNA looping
through physical interactions. Even though this is an energeti-
cally costly process (Saiz and Vilar, 2006), both short- and
long-range looping have now been extensively documented
(de Wit et al., 2013; Gheldof et al., 2010; Lieberman-Aiden
et al., 2009; Rao et al., 2014; Saiz and Vilar, 2006) and may
play an important yet poorly understood role in mediating long-
distance TF-DNA binding interdependencies.
It is therefore valuable to explore approaches to study the mo-
lecular origin of both short- and especially long-range TF-DNA
binding variation. One such approach is the identification of ge-
netic polymorphisms that significantly correlate with changes in
DNA occupancy. Genomic regions in which such variants are
located are interchangeably termed TF or binding quantitative
trait loci (tfQTLs or bQTLs), as their detection suggests that a
polymorphism within this locus causally affects the ability of a
TF to bind to DNA. One study adopting this approach aimed to
identify variants that affect DNA binding of the insulator protein
CTCF by profiling its binding landscape in human LCLs using
ChIP-seq, after which tfQTLswere exploredwithin a 50 kb region
centered around the CTCF binding region (Ding et al., 2014).
Only a minority of detected tfQTLs overlapped the CTCF motif,
even when the local LD structure was taken into account. A
similar picture emerged from a comparable study on PU.1
DNAbinding variation also in human LCLs, since PU.1 tfQTLs ex-
hibited a bimodal log-normal distribution in terms of their dis-
tance to the PU.1 binding region (Waszak et al., 2015). The first
mode represented tfQTLs that were located close to or at the
PU.1 binding site and, consistent with the CTCF study, encom-
passed only a minority of the significantly associated variants.
The second mode featured tfQTLs that were located distally to
the PU.1 binding region with a median distance between 20
and 30 kb. Together, these findings suggest that many variable
CTCF or PU.1 binding events are driven by long-distance mech-
anisms, which renders TF-DNA binding a complex molecular
trait by itself. Consequently, and even though the effect size of
distal tfQTLs tends to be inferior to that of proximal ones (Waszak
et al., 2015), it will be valuable to decipher how these distal var-
iants affect TF-DNA binding, given that they constitute themajor-
ity of DNA binding QTLs.
In the LCLs, PU.1 binding variation often correlated with vari-
ation in active chromatin marks such as H3K4me1 or H3K27ac—
not only locally, but often over extended distances (Waszak
et al., 2015). That is, high PU.1 DNA occupancy coincided with
both high proximal and distal H3K4me1 and H3K27ac enrich-
ment and vice versa. Such regions with a high level of molecular
coordination between TF and chromatin marks have recently
been termed ‘‘variable chromatin modules’’ (VCMs; Waszak
et al., 2015; Figure 3A). Each VCM is thus composed of molecu-
lar phenotypes (e.g., the level of DNA occupancy by a TF or
enrichment for a specific chromatin mark) that are highly coordi-
nated, often over multiple kbp of DNA. More than 14,000 distinct
VCMs were discovered in human LCLs, covering about 5% of
the genome (Waszak et al., 2015). Themajority of thesewere ‘‘to-
tem’’ VCMs—so named because they were composed of546 Cell 166, July 28, 2016stacked or overlapping molecular phenotypes that did not corre-
late with other neighboring molecular phenotypes. Thus, a totem
VCM represents local chromatin state variation (Figure 3A). The
remaining ‘‘multi-VCMs’’ are more interesting since, while a
minority, they typically cover two or more distinct regulatory ele-
ments—hence the term ‘‘multi’’—and capture the majority of all
detected molecular phenotypes (Figure 3A). The origin of a
‘‘multi- VCM’’ is less intuitive than that of a totem-VCM. Its struc-
ture suggests, however, a higher-order chromatin organization
that is reminiscent of the modular genomic structure that has
been uncovered in the form of topologically associating domains
(TADs) (Dixon et al., 2012; Nora et al., 2012).
These TADs constitute distinct, three-dimensional genomic
structures in which sequences are more likely to interact with
one another than with those located outside the respective
TAD. However, VCMs and TADs constitute different molecular
entities because VCMs tend to be embedded within TADs and
thus tend to be smaller (Waszak et al., 2015) (Figure 3B). In addi-
tion, TADs are relatively stable across cell types and during
development and are even conserved across species (Dixon
et al., 2012; Vietri Rudan et al., 2015), whereas VCMs are by defi-
nition variable. As such, multi-VCMs correspond conceptually
better to sub-TADs, which are more fine-grained (sub-Mb),
genomic topologies that have been shown to be dynamic across
cellular differentiation (Dixon et al., 2015; Phillips-Cremins et al.,
2013) and to even differ between individual cells (Giorgetti et al.,
2014). In addition, sub-TADs have been suggested to define cis-
regulatory networks (Berlivet et al., 2013), with their internal
conformational dynamics being directly related to embedded
transcriptional activity (Giorgetti et al., 2014; Tang et al., 2015).
In parallel, the vast majority of gene-associated multi-VCMs ex-
hibited amolecular activity state that significantly correlated with
the transcriptional activity of the included gene(s) (Waszak et al.,
2015) (Figure 3B). Moreover, the more regulatory elements
encompassed in a VCM, the more likely it was to associate
with variable gene expression. Together, the conceptual similar-
ities between sub-TADs and multi-VCMs suggest that the latter
also reflect fine-grained configurations of interacting regulatory
elements with one or a few target genes whose collective, mo-
lecular activity is highly coordinated. As such, VCMs may
provide substantial insights into the structural and thus modular
organization of the chromatin landscape, including TF-DNA
interactions.
Which mechanisms lie at the origin of multi-VCMs? Since the
long-range molecular coordination that typifies multi-VCMs has
been observed at the allelic level (Kasowski et al., 2013; Kilpinen
et al., 2013; McVicker et al., 2013) and since recent chromatin
interaction analysis by paired-end tag sequencing (ChIA-PET)
data has also provided evidence for allele-specific chromatin to-
pologies (Tang et al., 2015), it is reasonable to assume that the
observed molecular variation is largely driven by genetic factors.
Moreover, most of the molecular variation within each VCM
could be captured by a single, quantitative phenotype (Waszak
et al., 2015), which suggests that the activity state of a VCM
can be attributed to relatively few but strong causal variants.
QTL mapping using the activity state of each VCM as input
yielded vcmQTLs that were highly enriched in TF-occupied re-
gions (Waszak et al., 2015) (Figure 3A). Together with previous
Figure 3. Variable Chromatin Modules
(A) Correlated TF (e.g., PU.1 or RNA polymerase II [PolII]) binding and chromatin mark (e.g., H3K27Ac, H3K4me1, H3K4me3) enrichment analyses across in-
dividuals allows the mapping of ‘‘variable chromatin modules’’ (VCMs) (shown in light green in the upper panel and in network format in the panel below). VCMs
thus embody variable regions with highly coordinated, molecular phenotypes.
(B) The majority of VCMs have a ‘‘totem’’ structure of stacked molecular phenotypes that do not correlate with other neighboring molecular phenotypes and, as
such, reflect local chromatin state variation. Multi-VCMs encompass sub-Mb regions involving distinct regulatory elements whose activity is highly coordinated
and driven by a single or a few highly penetrating variants (‘‘vcmQTL’’) with enrichment in TF-bound regions.
(C) VCMs constitute functional entities of higher-order chromatin organization embedded within topologically associating domains (TADs) and provide a mo-
lecular rationale as to how TF-DNA binding can be affected by distal genetic variation.
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observations that TF-DNA binding perturbations are initiating
drivers of downstream changes in chromatin state and gene
expression (Kasowski et al., 2013; Kilpinen et al., 2013;McVicker
et al., 2013) (Table 1), these findings support amodel in which the
alteration of one or a few TF binding events affects all molecular
phenotypes in the respective VCM, including other embedded
TF-DNA interactions (Figure 3B). Thus, the ability of a TF to
bind to a VCM-associated genomic region appears to be a func-
tion of the respective VCM’s activity state, which itself seems
determined by one or few key TFs. As such, VCMsprovide a con-
ceptual framework to rationalize how distal genetic variation can
affect TF-DNA binding.
Defining these key TFs remains a work in progress, since only
few TFs reached significant enrichment in terms of their overlap
with vcmQTLs (Waszak et al., 2015). This suggests that each
VCM may have its own set of activity-determining TFs. Interest-
ingly, distinct pairs of these same TFs were also enriched at pairs
of regulatory elements that belonged to the same VCM (Waszak
et al., 2015), suggesting that the functional interactions between
these TFs (or among themselves) may be instrumental for form-
ing VCMs. Together, the presented findings support a scenario
in which the activity of each VCM is driven by a set of cell- and
chromatin-context-specific TFs. This would be consistent with
TF-DNA binding being highly dependent on proximal sequence
environment and chromatin organization, which may differ
from one VCM to the next. In addition, it would be compatible
with the ‘‘multiple enhancer variant’’ hypothesis (Corradin
et al., 2014), which dictates that linked variants in distinct regu-
latory elements often jointly contribute to gene expression varia-
tion. The VCM landscape may, as such, also be compatible with
the LD structure of the genome.
What is the molecular nature of VCM-embedded TF-TF inter-
actions? Based on the conceptual similarity between VCMs and
sub-TADs and on how canonical enhancer-promoter interac-
tions are established (Ciabrelli and Cavalli, 2015), it is conceiv-
able that they are mediated by either direct physical contacts
or by indirect protein-protein interactions involving more generic
factors such as mediator, CTCF, and cohesins (Dekker and
Mirny, 2016). The latter proteins may function to stabilize the
interactions both with DNA and between TFs such that
distal DNA binding interdependencies arise. However, other
interaction-independent mechanisms could also underwrite
such interdependencies, including long-range, transcription-,
or repression-coupled chromatin remodeling processes (Hath-
away et al., 2012; Smolle and Workman, 2013). Further experi-
mentation will be required to elucidate the involvement and
contributions of key individual TFs or TF pairs in VCM formation.
From Causal Variant to Complex Phenotype
While the identification and characterization of a trait- or dis-
ease-associated variant that causally disrupts TF-DNA binding
is difficult, elucidating how it impacts on other potentially down-
stream molecular and biological processes may be equally if not
more challenging (Edwards et al., 2013). One intuitive strategy to
expand on the relatively few cases so far in which a causal rela-
tionship betweenmolecular and phenotypic variation was estab-
lished (Table 1) is the integration of other genetic or molecular
data to infer the functional consequences of the focal variant.548 Cell 166, July 28, 2016For example, distinct QTL datasets can be used to determine
whether the variant impacts not only TF-DNA binding, but also
the chromatin landscape, gene expression, or even other molec-
ular phenotypes (Pai et al., 2015). The most common molecular
QTL analysis, involving the identification of variants that asso-
ciate with gene expression changes (i.e., eQTLs), is highly infor-
mative in this regard. For six distinct human populations, the
most significant eQTLs were consistently found to overlap TF
binding sites (Auton et al., 2015), thus providing direct insights
into the identity of genes whose expression may be affected
by variable TF-DNA binding.
However, other layers of molecular phenotypes—more asso-
ciated with regulatory functions and therefore often defined as
regulatory QTLs—can also be associated with genotypes. These
include: (1) DNase I sensitivity (ds)QTLs that are strongly en-
riched in predicted TF binding sites in addition to beingmajor de-
terminants of gene expression variation (Degner et al., 2012);
(2) chromatin (c)QTLs or histone marks (hm)QTLs that are largely
concordant with TF-DNA binding and transcription (Grubert
et al., 2015; Waszak et al., 2015), and (3) methylation (m)QTLs
that also often exhibit a functional link with the other regulatory
QTLs (Banovich et al., 2014; Domcke et al., 2015; Gutierrez-
Arcelus et al., 2013; Heyn et al., 2013; McClay et al., 2015). Since
regulatory QTLs as well as eQTLs were found to be enriched in
complex trait or disease susceptibility variants (Albert and Kru-
glyak, 2015; Grubert et al., 2015; Nicolae et al., 2010; Waszak
et al., 2015), their joint analysis may reveal how specific pertur-
bations triggered by causal genetic variants in a certain condition
or environment may first spread through transcriptional and
other molecular networks before affecting the cellular, tissue,
and finally organismal networks (Lehner, 2013; Mackay et al.,
2009).
An intriguing observation that emerged from such analyses is
that many regulatory QTLs do not overlap eQTLs, even if they
overlap other types of regulatory QTLs (Degner et al., 2012; Gru-
bert et al., 2015; Waszak et al., 2015). This is consistent with the
well-established finding that many changes in TF-DNA binding
have no measurable effect on gene expression (Cusanovich
et al., 2014; Farnham, 2009). Thus, regulatory QTL analyses suf-
fer from the same limitations as complex trait or disease suscep-
tibility GWAS studies, i.e., difficulties in uncovering leading
causal variants among LD blocks or in reaching statistical signif-
icance without a high number of samples (Veyrieras et al., 2008).
Approaches that link chromatin organization to transcriptional
function such as ChIA-PET (Dowen et al., 2014; Tang et al.,
2015) or VCM mapping (Waszak et al., 2015) may in this regard
prove valuable, as they can provide a structural framework for in-
terpreting regulatory variation. Indeed, as regulatory variants
tend to impact different layers of molecular phenotypes, it is
intrinsically valuable to know how these layers are coordinated
across distinct genomic domains. For example, many VCMs
were identified that consisted of active chromatin marks as
well as TF binding sites, even though an important portion of
such VCMs did not vary along with the expression of neighboring
genes. These VCMs, termed ‘‘island VCMs’’ (Waszak et al.,
2015), thus represent coordinated changes in TF binding and
chromatin state without measurable impact on gene expression.
Accordingly, QTLs for such island VCMs tend to overlap with
tfQTL and cQTLs, but not with eQTLs. There are several comple-
mentary hypotheses that could explain the existence of such
island VCMs, including (1) ‘‘futile’’ regulatory activity without
transcriptional consequences (Cusanovich et al., 2014; Farn-
ham, 2009; Wasserman and Sandelin, 2004); (2) regulatory
redundancy, which prevents a gene-specific regulatory network
from collapsing even if one node or edge is impacted (Pai et al.,
2015), consistent with the shadow enhancer concept (Hong
et al., 2008); (3) regulatory regions that are not transcriptionally
operational, at least in the studied condition/cellular environ-
ment, which implies that the activity of these regions is tissue
specific. Indeed, if, in a hypothetical study, a complex trait-asso-
ciated regulatory variant would be linked to an island VCM, it
might indicate that an incorrect system or context is being
studied, as its disconnection with gene expression is unlikely
to yield a cellular or organismal phenotype. This reasoning is
consistent with the observation across several studies that
GWAS variants tend to be most enriched for eQTLs in tissues
that are relevant to the phenotype (Emilsson et al., 2008; Nica
et al., 2010; Torres et al., 2014). However, in most cases, the
causal variants are obviously unknown a priori. To identify
them, it may prove valuable to, similar to eQTLs, map VCMs in
as many distinct cell types/tissues as possible. The resulting
set of VCMs may then provide guidance to both variant identifi-
cation and characterization. Indeed, the most interesting candi-
dates among the set of associated GWAS variants would be
those that impact not only on the chromatin topology (e.g.,
vcmQTLs) and state of the respective locus (e.g., cQTLs or
tfQTLs), but also on expression of the embedded gene. Once
identified, it should be relatively straightforward to detangle the
underlying molecular mechanisms since the coordinated, mo-
lecular phenotypes that make up the focal VCM should provide
clear insights into the flow of regulatory information, i.e., from
causal nucleotide over gene to ultimately cellular or organismal
phenotype.
Conclusions
The fundamental discovery that most complex trait-associated
variants are located in non-coding, putatively regulatory regions
of the genome has focused the spotlight on TF-DNA interactions
as important mediators of phenotypic variation. Yet, to date,
relatively few examples are available in which a clear mecha-
nistic relationship between TF-DNA binding variation and pheno-
typic variation was established (Table 1). To clarify why this is
such a challenging task, we focused in this Review on elucidating
how the impact of genetic variation on TF-DNA binding can be
assessed and why, contrary to expectations, this is itself already
inherently complex. There are several current limitations that will
have to be addressed to improve our ability to identify and inter-
pret regulatory variation, including the need for new experi-
mental or computational approaches that will enable us to
expand the TFmotif catalog, to better predict genuine TF binding
sites, and to evaluate how motif variation affects TF-DNA bind-
ing. Promising research avenues in this regard include the devel-
opment of new technologies to characterize monomeric and
higher complex TF-DNA binding properties and the incorpora-
tion of additional DNA binding features such as the sequence
environment and the conformational and chemical nature ofDNA in machine learning approaches. In addition, it is increas-
ingly appreciated that the chromatin context needs to be ac-
counted for when searching for causal, regulatory variants and
that, in general, the use of cell types or systems that are most
relevant for the studied trait or disease will yield the best results.
It is also important to recognize that only a small fraction of all
variable TF-DNA binding events is actually driven by variation
within the motif of the studied TF. Thus, similar to gene expres-
sion, TF-DNA binding is a complexmolecular trait by itself, which
has profound implications for our understanding of how regula-
tory variation arises.
Well-established concepts in the gene regulation field provide
an intuitive molecular foundation for local or proximal variant-
driven DNA binding variation. Specifically, the former involves
cooperative DNA binding that is mediated by direct, physical
interactions between TFs, while the latter appears to be driven
by collaborative DNA binding that is likely reflective of sequence-
or chromatin-context conditioned TF interdependencies to
displace nucleosomes and open chromatin. However, themech-
anisms that underlie distal variant-driven DNA binding changes
are much less well understood (Figure 2). The identification of
3C-, ChIA-PET-, or VCM-based chromatin entities that link
structural information to transcriptional function is important in
this regard since they offer a molecular rationale to explain these
prevalent, long-range DNA binding dependencies. Sustained
efforts will therefore be required to unravel the modular structure
of the variable (epi)genome across a wide range of cells or
tissues. Thus, although many challenges remain, exciting prog-
ress is being made in elucidating the genetic basis of TF-DNA
binding variation that will undoubtedly improve our ability to
achieve a nucleotide-level understanding of themolecularmech-
anisms underlying many complex traits, including disease
susceptibility.
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